0001193805-24-000426.txt : 20240321 0001193805-24-000426.hdr.sgml : 20240321 20240321172719 ACCESSION NUMBER: 0001193805-24-000426 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240319 FILED AS OF DATE: 20240321 DATE AS OF CHANGE: 20240321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chivukula Pad CENTRAL INDEX KEY: 0001727317 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38942 FILM NUMBER: 24772447 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcturus Therapeutics Holdings Inc. CENTRAL INDEX KEY: 0001768224 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8589002660 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 e619136_4-chivukula.xml X0508 4 2024-03-19 0 0001768224 Arcturus Therapeutics Holdings Inc. ARCT 0001727317 Chivukula Pad C/O ARCTURUS THERAPEUTICS HOLDINGS INC. 10628 SCIENCE CENTER DRIVE, SUITE 250 SAN DIEGO CA 92121 0 1 0 0 Chief Scientific Officer & COO 1 Common Stock 2024-03-19 4 S 0 8565 35.0075 D 490883 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Reflects the weighted average price of 8,565 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on March 19, 2024, with sale prices ranging from $35.00 to $35.02 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. /s/ Ilan Katz, attorney-in-fact 2024-03-21